The design goal of the ClearPoint Maestro® Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilit...
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell th...
“This submission is an important milestone for the ProMIS team as we advance our lead compound, PMN310, toward the clinic. We are excited to continue...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative pre...
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates targeti...
As previously announced on March 24, 2023, Sanofi commenced a cash tender offer to purchase all outstanding shares of common stock of Provention Bio, Inc. ...
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Clinical trials recruited hundreds of thousands of patients, while families in lockdown waited, hoping for regulatory approval of a COVID-19 vaccine that w...
Artificial Intelligence in Healthcare In healthcare, AI has the potential to drive scientific breakthroughs, aid in diagnosis, treatment, and management o...
Lyme disease is the most common vector-borne illness in the United States.2 And yet, the actual cases are vastly underreported. The U.S. Centers for Diseas...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...
Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset ...
BCs’ Act at the centre of this case aims to preserve a publicly-funded health care system where access to necessary medical care is based on patients...
Preclinical data demonstrate the efficacy of TNX‐801 vaccination against mpox virus challenge in a non-human primate model Phase 1 trial with TN...
© 2024 Biopharma Boardroom. All Rights Reserved.
